Human Transmembrane glycoprotein NMB(GPNMB) ELISA kit

Code CSB-EL009727HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
glycoprotein (transmembrane) nmb
Alternative Names
Glycoprotein (transmembrane) nmb ELISA Kit; Glycoprotein nmb ELISA Kit; Glycoprotein nmb like protein ELISA Kit; Gpnmb ELISA Kit; GPNMB_HUMAN ELISA Kit; HGFIN ELISA Kit; NMB ELISA Kit; Osteoactivin ELISA Kit; Transmembrane glycoprotein ELISA Kit; Transmembrane glycoprotein HGFIN ELISA Kit; Transmembrane glycoprotein NMB ELISA Kit
Abbreviation
GPNMB
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.78 ng/mL-50 ng/mL
Sensitivity
0.195 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cancer
Assay Principle
quantitative
Measurement
Sandwich
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This human GPNMB ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human GPNMB in serum, plasma, or tissue homogenates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the GPNMB levels in the sample and is measured at 450 nm through a microplate reader.

GPNMB has different functions on distinct cell types. In bones, GPNMB promotes differentiation of osteoblasts and mineralization of bone matrix, fibroblast activation, and proliferation, maturation of hematopoietic and lymphoid cells, and also decreases the activation of lymphocytes T. Also, GPNMB expression is detected in multiple other tissues such as kidney and skeletal muscle where it participates in various processes like cell proliferation, tumor progression, and tissue regeneration. In humans, GPNMB serum levels are related and contribute to obesity and metabolic parameters such as hip circumference, body mass index, and insulin resistance. GPNMB also has a function as a negative regulator of inflammatory processes. It has been associated with various pathological conditions such as colitis, nonalcoholic steatohepatitis, amyotrophic lateral sclerosis, glaucoma, neuroinflammation, and cancer progression.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Could be a melanogenic enzyme.
Gene References into Functions
  1. loss of GPNMB, which has been implicated in melanosome formation, autophagy, phagocytosis, tissue repair, and negative regulation of inflammation, underlies autosomal-recessive Amyloidosis cutis dyschromica. PMID: 29336782
  2. Study shows high GPNMB mRNA level in osteosarcoma tissues and cell lines. Its silencing regulates the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/Akt/mTOR signaling pathway. PMID: 29620278
  3. Serum levels of GPNMB were highly correlated with accumulation of bioactive lipid substrate of Gaucher disease, glucosylsphingosine as well as established biomarkers, chitotriosidase and chemokine, CCL18. PMID: 28003098
  4. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease PMID: 28391543
  5. This study revealed that GPNMB aggregates are localized to the neuron, and not localized to the astrocyte and microglia and in the spinal cord of ALS patients. GPNMB has protective effects against mutant TDP-43-induced motor neuron cell death, via ERK1/2 and Akt pathway.. PMID: 27935101
  6. This review will summarize the latest understanding of Gpnmb in the aspects of diagnosis, progression and prognosis of pathological disorders and neoplasms, emphasizing the clinical advances in targeting Gpnmb-expressing malignancies--{REVIEW} PMID: 29441921
  7. The combination of MAPK pathway inhibitors with an antibody-drug conjugate targeting GPNMB is an effective therapeutic option. PMID: 27515299
  8. High GPNMB expression is associated with enhancement of invasive behavior in lung cancer. PMID: 26883195
  9. Findings suggest that MAFK and its target gene GPNMB play important roles in the malignant progression of triple-negative breast cancer (TNBC) cells, offering potentially new therapeutic targets for TNBC patients. PMID: 28400538
  10. glycoprotein non-metastatic B presented increased expression in breast cancer in vivo compared to normal breast tissue PMID: 28689015
  11. Osteoactivin differential regulates the expression of matrix metalloproteases in head and neck squamous cell carcinomas to promote cancer cell invasion. PMID: 28295306
  12. The GPNMB is expressed in a temporal manner during eosinophil development and delivers a proliferative signal upon activation. PMID: 28104809
  13. it may be premature to conclude associations between GPNMB rs156429 and Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. PMID: 27132081
  14. Glycoprotein nonmetastatic melanoma protein B protein was highly expressed in the bladder cancer, which was related to the poor prognosis in bladder cancer patients. Glycoprotein nonmetastatic melanoma protein B promoted the proliferation, migration, and invasion in bladder cancer cells. PMID: 28443476
  15. an inducer for glioma and could enhance matrix metalloproteinase activity through Wnt/beta-catenin pathway to contribute to glioma tumorigenesis PMID: 27334625
  16. findings indicate that GPNMB promotes glioma growth via Na(+)/K(+)-ATPase alpha subunits. Thus, the interaction between GPNMB and Na(+), K(+)-ATPase alpha subunits represents a novel therapeutic target for the treatment of brain glioblastomas. PMID: 27836549
  17. Finally, we identify glycoprotein NMB as a melanocytic marker up-regulated in Tsc2-null mouse uteri and human lymphangioleiomyomatosis samples PMID: 26880751
  18. The GPNMB is a promising biomarker and therapeutic target for the development and progression of Nonalcoholic fatty liver disease in obesity. PMID: 26581806
  19. Osteoactivin in the extracellular matrix promotes oral squamous carcinoma cell adhesion and migration. PMID: 26636434
  20. Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease PMID: 26771826
  21. GPNMB might be a surrogate marker for BC and may cross talk with the HER2 signal pathway. PMID: 26077887
  22. GPNMB plays an important roles in regulating the expression of key pluripotency genes in dental pulp cells and modifying odontogenic differentiation. PMID: 26261527
  23. A positive correlation between GPNMB and NRP-1 levels in human breast tumors. PMID: 25772243
  24. Data shows that the expression of Gpnmb and Spp1 is highly upregulated in glioma-associated microglia/macrophages highlighting the importance of macrophages and microglia as therapeutic targets in anti-tumor treatment regimens. PMID: 25658639
  25. GPNMB/OA protein expression prevents cells from apoptosis-enhancing proliferation and represents a novel modulator of the invasion and metastasis in pancreatic cancer cells. PMID: 25426614
  26. The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. PMID: 25889792
  27. GPNMB mRNA in FLCN-related renal cell carcinomas was 23-fold more abundant than in sporadic tumors. PMID: 25594584
  28. GPNMB has protective effect against ischemia-reperfusion injury via phosphorylation of ERK1/2 and Akt PMID: 25010402
  29. Glycoprotein nonmetastatic melanoma protein B plays an important role in angiogenesis during hyperoxia injury PMID: 25054912
  30. DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma PMID: 24933321
  31. Our data identify Gpnmb as a novel marker for obesity-induced adipose tissue macrophage infiltration and potentiator of interleukin-4 responses and point toward a crucial role for MITF in driving part of the adipose tissue macrophage phenotype. PMID: 24789918
  32. GPNMB/OA acts as a critical molecular mediator promoting the acquisition of the more aggressive, pro-metastatic phenotype distinctive of human DU145 and PC3 cell lines. PMID: 24589892
  33. our findings will clarify a new explanation about how GPNMB induces bone repair, and provide a potential target for bone regeneration therapeutics and bone engineering PMID: 23794283
  34. the molecular basis for the distinct trafficking and morphogenetic properties of PMEL and GPNMB is the PKD domain PMID: 23452376
  35. GPNMB expression was regulated by EpCAM and CSF-1 partly through their common downstream product c-myc PMID: 23924854
  36. Silencing of GPNMB by siRNA inhibits the formation of melanosomes in melanocytes in a MITF-independent fashion. PMID: 22912767
  37. GPNMB inhibits motor neuron death and plays a critical role in motor neuron survival. PMID: 22891158
  38. Together these results suggest that GPNMB gene is a p53- and androgen-dysregulated gene and should be regarded as an anti-tumor gene for prostate cancer. PMID: 22290289
  39. The abnormal expression of GPNMB may play an important role in the development of prostate cancer. PMID: 21844952
  40. Gastrointestinal stromal tumours do not show immunopositivity for ERa or HMB45. PMID: 22014058
  41. upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors PMID: 21874302
  42. GPNMB increase in kidney disease was confirmed by real-time PCR after 5/6 nephrectomy, in streptozotocin-induced diabetes, and in patients with chronic kidney disease PMID: 21389974
  43. Toxin-conjugated DC-HIL to abrogate the ability of Sezary syndrome cells to proliferate in vitro. PMID: 21252093
  44. ADAM10 as a sheddase capable of releasing the GPNMB/OA ectodomain from the surface of breast cancer cells PMID: 20711474
  45. GPNMB expression has a role in uveal melanoma PMID: 20375921
  46. GPNMB expression is associated with the basal/triple-negative subtype and is a prognostic marker of poor outcome in patients with breast cancer. PMID: 20215530
  47. GPNMB is a melanosomal protein that is released by proteolytic ectodomain shedding and might be a useful and specific histological marker of melanocytic cells. PMID: 20056711
  48. Human OA uses the same transcriptional initiation site in both bone and kidney as was reported for melanoma cells and is expressed in osteoblast cultures at all stages of differentiation PMID: 14696968
  49. cloning and analysis of two fragments in the 5' flanking region of HGFIN; studies indicate p53 cooperates with cytokine-mediated transcription factors to regulate the expression of HGFIN PMID: 15684612
  50. Osteoactivin is expressed at high levels in normal and inflammatory liver macrophages suggesting a significant role in acute liver injury. PMID: 15763343

Show More

Hide All

Involvement in disease
Glioblastoma multiforme patients that exhibit increased mRNA and protein levels (>3-fold over normal brain) in biopsy samples have a significantly higher risk of death (PubMed:16609006). In the context of cancer immunotherapy, including that of melanoma, has been proposed to be used as a cell surface protein antigen targeted by antibodies coupled to cytotoxic drugs (PubMed:16489096).
Subcellular Location
Cell membrane; Single-pass type I membrane protein. Melanosome membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein.
Protein Families
PMEL/NMB family
Tissue Specificity
Widely expressed, but very low expression, if any, in the brain. Expressed in the epidermis with higher levels in melanocytes compared with keratinocytes and Langerhans cells (at protein level). Expressed in peripheral blood, but not bone marrow mononucle
Database Links

HGNC: 4462

OMIM: 604368

KEGG: hsa:10457

STRING: 9606.ENSP00000371420

UniGene: Hs.190495

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1